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Abstract
Transforming growth factor-h (TGF-h) has been identified as a key mediator of glomerulosclerosis in kidney diseases. Endoglin is a
component of the TGF-h receptor system that is upregulated during glomerulosclerosis, suggesting a role during progression of renal
diseases characterized by extracellular matrix (ECM) synthesis and accumulation. The expression of endoglin was demonstrated in cultured
human mesangial cells (HMC) by flow cytometry, Northern blot, reverse transcriptase polymerase chain reaction (RT-PCR), and Western blot
analyses. TGF-h upregulated not only the expression of endoglin, but also that of TGF-h itself, TGF-h receptor type II, collagen I, collagen
IV, and fibronectin. To study the role of endoglin in TGF-h responses, transfectant fibroblasts overexpressing endoglin were analyzed.
Untreated and TGF-h-treated endoglin + cells showed significantly lower levels of collagens than those in control cells, indicating that
endoglin negatively regulates ECM levels of collagens. These findings may have important implications in the pathological states associated
with renal fibrosis. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The molecular basis responsible for the progression of
kidney diseases to end-stage renal failure remains still
obscure. Glomerular and tubulointerstitial fibrosis charac-
terized by excessive accumulation of extracellular matrix
(ECM) appears to occur independently of the primary
underlying disorder. The ability of glomerular mesangial
cells (GCM) to modulate their proliferative phenotype and
secrete ECM supports their crucial role in the development
and progression of the glomerular disorder [1]. These
aspects of GCM behavior can be modified by transforming
growth factor beta 1 (TGF-h1), a multifunctional cytokine
that modulates proliferation, morphogenesis, development,
injury, and repair [2,3]. Thus, TGF-h has been identified as
a key mediator of glomerulosclerosis in both experimental
animal models and human kidney diseases [4,5]. In various
cell types, TGF-h promotes the transcription, synthesis and
secretion of numerous proteins of the ECM including
collagens, fibronectin, and proteoglycans [6,7]. It also
decreases the degradation of ECM molecules by down-
regulating ECM-degrading proteases, stimulating synthesis
of protease inhibitors and increasing transcription and ex-
pression of integrins that are receptors for ECM molecules
[6,8]. The ECM provides a structural basis for multicellu-
larity, whereas growth factors facilitate the transfer of
information required for construction of the complex cellu-
lar network. In this sense, some authors postulate that ECM
plays a major role in the control of growth factor signaling
[9], and immunohistochemical studies have suggested that
TGF-h associates with interstitial ECM and basement mem-
branes [10].
Members of the TGF-h superfamily exert their function
through binding to specific receptors, including receptors
type I (R-I), type II (R-II), betaglycan, and endoglin [11].
Among these, the serine-threonine kinase receptors type I
and II are necessary for all tested biological responses to
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TGF-h [12,13]. Thus, TGF-h binding to the constitutively
phosphorylated R-II is followed by recruitment of R-I into
the complex, phosphorylation of R-I, and propagation of the
signal to downstream substrates of the Smad family of
proteins [14].
Endoglin is a 180-kDa homodimeric membrane glyco-
protein expressed by human endothelial cells [15], macro-
phages [16], stromal cells [17,18], and vascular smooth
muscle cells [19–21]. The gene encoding endoglin has been
identified as the target gene for the autosomal dominant
vascular disorder known as Hereditary Hemorrhagic Telan-
giectasia type 1 [22]. Endoglin binds at least TGF-h1, TGF-
h3, activin, BMP-2, and BMP-7 [23,24]. Two different
isoforms, L-endoglin and S-endoglin, with the capacity to
bind TGF-h but differing in the amino acid composition of
their cytoplasmic tails, have been characterized [25,26]. As
endoglin is able to modulate cellular responses to TGF-h
[27–29], the presence of endoglin in different TGF-h-mod-
ulated cell types suggests its possible regulatory ability.
Among resident renal cells, mesangial cells are well-defined
targets for TGF-h and play a central role in the development
of glomerular sclerosis. The possible role for endoglin in the
genesis of this process has been poorly evaluated. In the
present study, we have investigated the expression of endo-
glin mRNA and protein in human mesangial cells (HMC), as
well as its possible role in the dynamic equilibrium of
synthesis and degradation of ECM. We propose that the
expression of endoglin may have a role in regulating the
effects of TGF-h in HMC.
2. Materials and methods
2.1. Cell culture
HMC were cultured according to previously described
procedures [30], with minor modifications. Portions of mac-
roscopically normal cortical tissue were obtained from
human kidney immediately after nephrectomy. The cortex
was cut into slices and washed twice to remove contaminat-
ing blood. The material was successively pushed through
180- and 105-Am stainless steel sieves and washed to obtain
isolated glomeruli free of tubular contamination. Hank’s
Balanced Salt Solution (HBSS) was used in all steps of the
glomerular isolation procedure. Glomeruli were then treated
with collagenase (Sigma Chemicals, St. Louis, MO), plated
in plastic culture dishes, and maintained in RPMI 1640
supplemented with 10% fetal calf serum (FCS), 1 mM L-
glutamine, 100 units/ml penicillin, and 60 Ag/ml strepto-
mycin sulfate. Cells were buffered with HEPES and bicar-
bonate, pH 7.4, and grown in a 5% CO2 atmosphere. Culture
media were changed every 2 days. When cells reached con-
fluency, they were subcultured at a ratio of 1:4 using the same
incubation medium. The experiments were performed in
passages 10–12. The identity of HMC was confirmed by
morphological and functional criteria as previously described
[31]. Additional studies were performed in cells cultured on
two-dimensional type I or IV collagen films [32]. For this
purpose, Petri dishes were treated for 16 h with a solution
containing 12.5 Ag/ml collagen I or collagen IV (Sigma) in
bicarbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH
9), washed with HBSS to restore the pH 7.5, and seeded
with trypsinized cells. After 48 h, cells were serum-
deprived for 24 h, and total RNA extracted. For TGF-h
treatments, HMC were serum-deprived for 24 h, followed
by incubation in serum-free medium containing 1–10 ng/ml
TGF-h1 (R&D Systems) for an additional period of 24 h, as
indicated.
Human umbilical vein endothelial cells (HUVEC) were
isolated from cannulated vessels incubated in the presence of
collagenase for 20 min at 37 jC. Detached cells were plated
in gelatin-coated flasks and grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat
inactivated FCS.
The mouse fibroblast cell line L929 was cultured in
DMEM supplemented with 10% heat-inactivated FCS, 2
mM L-glutamine, and 100 units/ml penicillin in a 5% CO2
atmosphere at 37 jC. The generation of L929 fibroblast
transfectants expressing human endoglin has been previ-
ously described [26]. Mock and endoglin-transfected (endo-
glin + ) fibroblasts were grown with complete DMEM
medium in the presence of 400 Ag/ml of the antibiotic
G418. For TGF-h treatments, cells were plated in 60-mm
culture dishes at 4 105 cells/dish. Twenty four hours later,
cells were serum-starved for 24 h prior incubation with 1 or
10 ng/ml TGF-h1 in serum-free medium for 24–48 h.
Collagen synthesis was quantified by measuring the incor-
poration of [3H]-proline to collagen proteins, as described
elsewhere [33]. a2(I) collagen mRNA levels were measured
by Northern blot as described below.
2.2. Analysis of endoglin mRNA expression by reverse
transcriptase polymerase chain reaction (RT-PCR)
Endoglin mRNA expression in cultured HMC was meas-
ured by using the RT-PCR assay. In every case, total RNA
was extracted from cells, according to the method of
Chomczynsky and Sacchi [34], and both the quantity and
the quality of the RNA were verified by ethidium bromide-
staining of mRNA bands on an agarose minigel.
The amplification of L-endoglin was achieved using
E#11R primer 5V-CTGGGTCGAGTGGAGGACTG-3V and
E#12R primer 5V-CAAGACCGGGTCTCAAGACC-3V.
Two micrograms of total RNA was reverse-transcribed by
incubating at 42 jC for 30 min (RNA PCR kit; Roche
Molecular Biochemicals). For polymerase chain reaction
(PCR), the cDNA obtained after the RT reaction was
amplified with the L-endoglin primers and combined with
0.2 mM of each deoxynucleotide triphosphate in 100 Al
solution that contained 1 PCR buffer, 2 mM MgCl2, and
2.5 U of Taq DNA polymerase. PCR was programmed for 1
cycle at 95 jC 5 min, 35 cycles at 95, 55, 72 jC of 1 min 30
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s, respectively, and 1 cycle at 72 jC 10 min. The amplified
cDNAs were electrophoresed through a 1.5% agarose gel.
PCR amplification yielded a single band corresponding to a
414-bp cDNA fragment whose sequence analysis confirmed
its identity with human L-endoglin [26]. Contamination was
ruled out by a negative PCR when the reverse-transcription
step was omitted.
2.3. Analysis of mRNA expressions by Northern blot
HMC or mouse fibroblasts were homogenized using gua-
nidinium isothiocyanate, and total RNA was isolated by re-
peated phenol–chloroform extractions and isopropanol pre-
cipitation as described [34]. Total RNA (10 Ag per lane) was
denatured by heating in formamide/formaldehyde at 100 jC
for 3 min and electrophoresed through a 1% agarose gel
containing 0.66 M formaldehyde. The RNAwas transferred
to nitrocellulose membrane (Amersham Biosciences) by
capillary blotting and ultraviolet hybridizations were per-
formed in a rotating drum in a temperature-controlled oven.
The membranes were prehybridized at 42 jC for 24 h in 5
SSPE (20 SSPE: 3 M NaCl, 0.2 M NaH2PO4, 0.02 M
EDTA), 5 Denhardt’s solution (50 Denhardt’s: 1%
Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin,
50% formamide, 0.1% SDS), and 0.1 mg/ml denatured
salmon sperm DNA. cDNA inserts were radiolabeled with
5 ACi a32P-dCTP (3000 Ci/mmol; Amersham Biosciences)
using a radiolabeling system (Rediprime; Amersham Bio-
sciences). Mouse a1(IV) collagen probe was kindly provided
by Dr. Kurkinen (Detroit, MI). The cDNA probes encoding
mouse TGF-h1, fibronectin, and rat a2(I) collagen were gifts
from Dr. Ziyadeh (Philadelphia, PA), and human L-endoglin
probe was synthesized by the PCR using human kidney as
described above. Blots were hybridized for 24 h with 106
cpm/ml probe at 42 jC in the same buffer used for prehy-
bridization. Then, membranes were washed twice for 5 min
each in 2 SSC (20 SSC: 3 M NaCl, 0.3 M sodium
citrate, pH 7.0) and 0.5% SDS at 42 jC and then for 5 min in
1 SSC, 0.5% SDS at 42 jC. Autoradiography was
performed with intensifying screens (X-OMAT, Kodak) at
 80 jC for 24–48 h. Blots were stripped for 30 min in 0.1%
SDS, 0.1 SSC at 100 jC and re-hybridized with the
remaining probes listed. Densitometric analysis of the
exposed films was performed with an Apple scanner and
appropriate software (NIH Image 1.55 from the National
Institutes of Health).
2.4. Flow cytometry
HMC were incubated with either a rabbit polyclonal
antibody to human endoglin [35] at 1:1000 dilution, or with
the mouse monoclonal antibody W6/32 against the human
major histocompatibility antigen type I (Sigma) for 30 min
at 4 jC. After two washes with PBS, FITC-labeled F(abV)2
rabbit anti-mouse Ig or swine anti-rabbit Ig (Dakopatts) was
added and incubation proceeded for an additional period of
30 min at 4 jC. Finally, cells were washed twice with PBS
and their fluorescence was estimated with an EPICS-CS
(Coulter Cientifica, Mostoles, Spain), using logarithmic
amplifiers. Nonspecific rabbit and mouse immunoglobulins
were also used as negative controls.
2.5. Western blot analysis
HMC or rat myoblast stable transfectants expressing
human L-endoglin [28], were cultured to 70–80% conflu-
ency, trypsinized, collected by centrifugation, and solubi-
lized in lysis buffer (10 mM Tris–HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 10 Ag/ml pepstatin,
50 Ag/ml leupeptin, 1 mM benzamidine and 1 mM phenyl-
methylsulfonyl fluoride), for 40 min al 4 jC. Total extracts
(30–60 Ag/lane) were subjected to SDS-PAGE on 7.5%
polyacrylamide gels under either reducing or nonreducing
conditions. Proteins were electrophoretically transferred to
nitrocellulose membranes (Millipore Corp., Bedford, MA,
USA). Filters were blocked with PBS containing 5% milk
powder for 1 h. Specific immunodetection was carried out
by incubation with a rabbit polyclonal antibody to human
endoglin [35], or the corresponding pre-immune antibody,
followed by peroxidase-conjugated goat anti-rabbit Ig at
room temperature. The presence of endoglin was detected
using a chemiluminescence assay (ECL detection kit; Amer-
sham Biosciences).
2.6. Statistical analysis
Results shown are the meanF S.E., and n = number of
experiments (see figure legends). The Northern blot densi-
tometry data were corrected for variations in gel loading by
accounting for the relative intensities of the 18 S band or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
When n < 10, nonparametric statistics were used for com-
parisons (Friedman’s and Wilcoxon’s tests). A P < 0.05 was
considered statistically significant.
3. Results
3.1. Expression of endoglin in HMC
Mesangial cells obtained from human kidney after neph-
rectomy were analyzed for endoglin expression. As shown
in Fig. 1A, endoglin transcripts were detected by RT-PCR in
quiescent cultured HMC. Using specific primers to human
endoglin, a single 416-bp PCR product of the predicted size
corresponding to the L-endoglin isoform was obtained. To
confirm that this band represented endoglin, it was purified,
cloned into pCR-Script SK(+) plasmid, and sequenced.
Moreover, endoglin was expressed on the surface of the
HMC (Fig. 1B). The analysis by flow cytometry using a
rabbit polyclonal antibody to human endoglin demonstrated
the expression of the protein on the cell membrane, suggest-
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ing a possible functional role in the TGF-h receptor system.
The presence of endoglin in HMC was further confirmed by
Western blot under reducing (R) or nonreducing (NR)
conditions, indicating that HMC endoglin naturally appears
in a dimeric form (Fig. 1C).
3.2. TGF-h1 regulates the expression of endoglin, R-II and
TGF-h
TGF-h is known to regulate its own expression, as well
as that of TGF-h receptor components, including endoglin
Fig. 1. Expression of endoglin in HMC. (A) Detection of endoglin transcripts by PCR amplification. Samples of total RNA from HMC or HUVEC were
incubated either in the presence (+) or in the absence ( ) of reverse transcriptase. The generated cDNA samples were used for PCR amplification in the
presence of specific primers to human endoglin and L-endoglin. A single 416-bp band corresponding to the L-endoglin isoform was obtained from HMC,
whereas amplification from control HUVEC resulted in the amplification of both isoforms. The 416-bp PCR product from mesangial cells was purified, cloned,
and sequenced to confirm the endoglin identity. (B) Analysis by flow cytometry of endoglin present at the cell surface. HMC were incubated with a rabbit
polyclonal antibody to human endoglin or with the mouse monoclonal antibody W6/32 against the human major histocompatibility antigen type I (HLA-I),
followed by incubation with the corresponding secondary FITC-labeled F(abV)2 anti-Ig. Nonspecific rabbit (Control-R) or mouse (Control-M) antibodies were
used as negative controls. (C) Western blot analysis. Myoblast transfectants expressing endoglin (T) or HMC (M) were lysed and total extracts were
electrophoretically separated under reducing (R) or nonreducing (NR) conditions. Proteins were transferred to nitrocellulose and specific immunodetection was
carried out by incubation with a polyclonal antibody to endoglin (anti-endoglin) or a preimmune antibody (Control), followed by peroxidase-conjugated goat
anti-rabbit Ig. Endoglin was detected using a chemiluminescence assay. Arrowheads indicate the position of endoglin dimer (170 kDa) or endoglin monomer
(80 kDa). The band with higher electrophoretic mobility than the endoglin monomer is nonspecific as it is also present in the negative control.
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Fig. 2. Effects of TGF-h1 on endoglin, R-II, and TGF-h expression in
cultured HMC. Cells were deprived of serum for 24 h and incubated in the
absence (C) or in the presence (1 or 10 ng/ml) of TGF-h1 for an additional
period of 24 h. The mRNA expression was analyzed by Northern blot. In
each sample, the densitometric analysis of endoglin (END), R-II, or TGF-h
mRNA expression was corrected with their respective GAPDH mRNA
levels. Results are expressed as percent of control values and represent the
meanF S.D. of three different experiments. *P < 0.05 vs. control. Transcript
levels of endoglin, R-II, and TGF-h are shown in panels A, B, and C,
respectively.
Fig. 3. Effects of TGF-h1 on fibronectin, collagen I, and collagen IV in
cultured HMC. Cells were deprived of serum for 24 h and incubated in the
absence (C) or in the presence (1 or 10 ng/ml) of TGF-h1 for an additional
period of 24 h. The mRNA expression was analyzed by Northern blot. In
each sample, the densitometric analysis of fibronectin (FN), collagen I
(COL I), or collagen IV (COL IV) mRNA levels was corrected with their
respective GAPDH mRNA levels. Results are expressed as percent of
control values and represent the meanF S.D. of three different experi-
ments. *P< 0.05 vs. control.
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[10,27,36]. Thus, the modulation of endoglin and receptor
type II mRNA expression by TGF-h1 in quiescent cultured
HMC was evaluated by Northern blot analysis (Fig. 2A,B).
Two different concentrations of TGF-h1 (1 and 10 ng/ml)
induced an increase in mRNA levels of endoglin and
receptor type II after 24-h incubation, and scanning densi-
tometry demonstrated quantitatively this increase. More-
over, the mRNA expression of TGF-h1 increased in the
presence of TGF-h1 ligand (Fig. 2C). These results dem-
onstrate that TGF-h modulates the expression of the TGF-h
receptor components in HMC, including endoglin, suggest-
ing a functional role for endoglin in other TGF-h responses.
In addition, the autocrine regulation by TGF-h is compatible
with the maintenance of the TGF-h effects within the time
period studied.
3.3. Effects of TGF-h1 on the expression of ECM proteins in
HMC
Given the critical role that mesangial cells play in the
glomerular and interstitial fibrosis characterized by an excess
of ECM, we analyzed whether TGF-h could modulate the
expression of several ECM components. As shown in Fig. 3,
treatment of HMC with TGF-h1 showed a marked increase
of the mRNA levels of fibronectin, collagens I and IV. These
results are in agreement with previous reports [37] and
support a relevant role for TGF-h in modulating mesangial
cell’s functions.
3.4. ECM composition affects endoglin expression in HMC
Since TGF-h is able to affect the expression and thereby
the composition of the ECM proteins, we wondered whether
the presence of collagen types I or IV would in turn differ-
entially affect the expression of endoglin in HMC. Cells
were grown either in the absence or in the presence of
collagen type I or IV as substrates. After 24 h in culture,
the levels of endoglin mRNAwere analyzed by Northern blot
(Fig. 4). Both collagen substrates significantly increased the
expression of endoglin mRNA levels with respect to the
uncoated control. Interestingly, endoglin transcripts were
increased in the presence of collagen IVat higher levels than
with collagen I. Since collagen IV is the major component of
the ECM within the mesangium, these results suggest that
this environment favors the expression and therefore the
function of endoglin.
Fig. 4. Effects of collagen I and collagen IV substrates on endoglin mRNA
expression in cultured HMC. Cells were plated on dishes previously coated
or not with collagen I (COL I) and collagen IV (COL IV), as indicated.
After 24 h in culture, cells were harvested, endoglin (END) and GAPDH
mRNA levels were analyzed by Northern blot, and the intensity of specific
bands was quantified by densitometry. Results are expressed as percent of
control values and represent the meanF S.D. of three different experi-
ments. *P < 0.05 vs. control.
Fig. 5. Effect of endoglin on TGF-h1-induced protein and mRNA levels of
collagen. (A) Collagen synthesis. Mock and endoglin + fibroblast trans-
fectants were serum-starved for 24 h prior addition of 10 ng/ml TGF-h1 in
serum-free medium. Incubation in the presence of TGF-h1 was carried out
for an additional period of 48 h, and collagen synthesis was quantified
by measuring the incorporation of [3H]-proline. Results represent the
meanF S.D. of three different experiments. *P < 0.05 vs. mock control.
Open bars: Cells cultured in the absence of exogenous TGF-h1. Hatched
bars: Cells cultured in the presence of 10 ng/ml TGF-h1. (B) Northern blot
analysis. Mock and endoglin + fibroblast transfectants were serum-starved
for 24 h prior to addition of 1–100 ng/ml TGF-h1 in serum-free medium,
as indicated. Incubation was carried out for an additional period of 24 h,
cells were harvested and the collagen (COL I) mRNA expression was
analyzed by Northern blot. As an internal control, RNA blots were
hybridized with a probe specific for 18S RNA. A representative experiment
out of three different ones is shown.
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3.5. Role of endoglin in the TGF-h1-induced production of
collagen
To study the role of endoglin in TGF-h-dependent
responses of mesangial cells, we tried unsuccessfully to
obtain stable transfectants overexpressing endoglin in this
cell lineage. Therefore, we decided to use fibroblast trans-
fectants overexpressing human endoglin that have been
previously described [26]. In addition to serving as a model
to study endoglin function, this cell type has the advantage of
being a critical cellular component of the interstitial fibrosis
occurring in several pathological conditions within the
kidney. Thus, mock and endoglin + transfectants were incu-
bated either in the absence or in the presence of TGF-h1 and
48 h later, the expression of collagen was analyzed. As
expected, treatment with TGF-h1 increased the levels of
collagen synthesis, as measured by proline incorporation, in
both types of fibroblasts (Fig. 5A). However, collagen levels
in untreated and TGF-h-treated endoglin + cells were sig-
nificantly lower than those in control cells. This is in agree-
ment with a previous report showing similar results with
fibronectin using the same transfectants [38], suggesting that
endoglin is regulating the autocrine TGF-h pathway. Fur-
thermore, Northern blot analyses revealed that the induc-
tion of collagen I by TGF-h1 in endoglin + fibroblasts was
clearly lower than that of mock transfectants (Fig. 5B).
Taken together, these results suggest that endoglin negatively
regulates the ECM levels of collagens.
4. Discussion
The key contribution of TGF-h1 during the progression
of chronic renal disease to glomerulosclerosis and interstitial
fibrosis is well established [39,40]. TGF-h1 is a major pro-
fibrogenic factor able to induce synthesis and accumulation
of several ECM components, including collagens, fibronec-
tin, and PAI-1 [36,39,41,42]. Thus, study of the TGF-h
system is very important to understand the renal fibrogenic
process. The auxiliary TGF-h receptor endoglin is able to
modulate several TGF-h cellular responses [27–29] and is
highly expressed in the vasculature, where it plays an
important role in vascular remodelling and homeostasis.
This is evidenced by the fact that homozygous endoglin
KO mice die at day 9.5 after gestation due to cardiovascular
defects [43–45], and that mutations in the endoglin gene are
responsible for the Hereditary Hemorrhagic Telangiectasia
type 1, a disease associated with telangiectases in skin and
mucosas and arteriovenous malformations in lung, liver, and
brain [22,46]. Endoglin has been shown to be upregulated in
diseased human kidney with glomerulonephritis [47], and in
rat kidney with glomerular sclerosis induced by renal mass
reduction [48]. In addition, expression of endoglin has been
detected in human and rat mesangial cells in culture [49].
Here we have extended these findings by analyzing for the
first time endoglin expression in HMC by Northern blot and
RT-PCR analyses. We find that endoglin is constitutively
expressed at the surface of HMC, but it can be upregulated
Fig. 6. Schematic representation of a possible model of the TGF-h system in renal pathophysiology. Soluble TGF-h induces expression of ECM components,
TGF-h, TGF-h signaling receptors, and endoglin in mesangial cells. Accumulation of ECM can lead to glomerulosclerosis, unless action of TGF-h is
counterbalanced. Endoglin probably participates in repair and remodelling by downregulating TGF-h signaling.
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by TGF-h1, in agreement with previous reports in human
monocytic [27] and rat mesangial [49] cells. TGF-h1 not
only upregulated endoglin expression, but also fibronectin,
collagen type I, collagen type IV, and TGF-h itself in HMC,
resembling the in vivo situation of the glomerulosclerosis.
This is in agreement with previous results obtained with cell
types from different lineages [7]. The importance of the
TGF-h-induced modulation of these ECM components is
supported by the fact that collagen I is the predominant
structural component in all tissues, accounting for 90% of all
collagens, whereas collagen IV is an essential component of
the basal lamina [50]. In this regard, it has been reported that
mesangial cells in culture behave differently with respect to
their proliferative phenotype and contractile response,
depending on whether they are cultured on mesangial matrix
or collagen I [51]. Within the mesangium, collagen IV is the
major ECM component, while collagens I and III are almost
absent from the healthy glomerulus. However, upon the
glomerular sclerosis associated with the ageing process,
interstitial collagens I and III are induced [52]. Thus, it is
tempting to speculate that endoglin is involved in the ECM
synthesis by mesangial cells.
To understand the upregulation and function of the TGF-
h receptor component endoglin by TGF-h, we analyzed the
effect of endoglin overexpression in cell transfectants. In the
absence of a commercially available stable mesangial cell
line, we used mouse fibroblasts stably transfected with
human endoglin [26]. When the TGF-h response was
analyzed in these transfectants, the collagen synthesis was
found to be decreased respect to mock transfected cells,
suggesting a negative role for endoglin in the TGF-h-
induced ECM production. Similarly, other TGF-h responses
have been found to be negatively regulated by endoglin in
human monocytes [27], human endothelial cells [29], and rat
myoblasts [28].
Two different lines of evidence support the role of
endoglin in renal pathological states: (a) endoglin has been
shown to be upregulated in human kidney with glomerulo-
nephritis [47], and in rat kidney with glomerular sclerosis
induced by renal mass reduction [48]; and (b) certain
patients with Hereditary Hemorrhagic Telangiectasia, a
disease where endoglin expression is haploinsufficient, dis-
play a chronic renal disease pattern [53,54], and marked
hepatic fibrosis [55]. In view of the results presented in this
paper and previous reports [27–29,49], a model can be
proposed for the role of endoglin in renal fibrosis (Fig. 6).
Thus, TGF-h upregulates the expression of endoglin in
mesangial cells, and in turn, endoglin would counterbalance
the induction of ECM components by TGF-h. The result is
that endoglin would negatively affect the progression in
glomerulosclerosis. It is noteworthy that TGF-h binds to
proteoglycans in the matrix or near the cell surface, and such
binding may also act as a negative signal to terminate the
production of TGF-h after tissue repair is complete [9,56].
In this sense, injection of the proteoglycan decorin into
nephritic rats was as effective as the administration of anti-
TGF-h1 in inhibiting glomerular accumulation of ECM
[57]. On the other hand, the composition of the TGF-h-
induced ECM might affect the equilibrium between pro-
gression or repair of glomerulosclerosis. A collagen IV, but
not a collagen I, -enriched ECM would allow upregulation
of endoglin facilitating the repair process. It will be inter-
esting to determine the specific molecular mechanisms by
which endoglin is modulating the outcome of renal disease.
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